Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study of RX-3117
08:00 EDT 6 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company commercializing potential best in class oncology
and CNS therapeutics, today announced that it has completed its
exploratory Phase I clinical...
Other Sources for this Article
Rexahn Pharmaceuticals, Inc.
Investor Relations
Base
Pair Communications
Constantine Theodoropulos, 617-816-4637
constantine@basepaircomm.com
More From BioPortfolio on "Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study of RX-3117"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
